DVD

L/S equity HF Mgr. | Macroeconomics | Special Situation Investor | Nothing written by this account is financial advice, do your own research

[DVD @deepvaluedude]

$ASTS $VOD
🧵Vodafone Investment Thesis
Current Price (2H FY26): $13
FY28 PT: ~$23
The Thesis in Brief: Vodafone has successfully transitioned from a distressed conglomerate into a disciplined, growth-focused connectivity platform. The market is currently pricing VOD on backwards-looking metrics; fixated on the painful German MDU transition and historical debt bloat. This creates a dislocation. This view identifies three mispriced levers that will drive a re-rating in FY27 and continued multiple expansion beyond:
Germany Turns the Corner: The operational drag from the TV Law change is fully priced in. FY27 represents the first clean year of EBITDA growth in the core German market.
The "SatCo" Option: The joint venture with AST SpaceMobile is currently valued at zero by consensus. We view it as a high-margin infrastructure monopoly for European Direct-to-Device (D2D) connectivity, worth ~$2.00/share alone on FY28 EBITDA estimates discounted backwards.
Capital Discipline as a Floor: The massive share buyback program (reducing float by ~15% vs. FY24) provides a mechanical floor to the stock price, while structurally lowering the dividend burden.

[DVD @deepvaluedude]

$MRLN
I’ll leave this right here.

[Ry🅰️n O'Connor @AboveAvgOdds]

@mc_khristina Hard to imagine how we don’t 2-3x on the news given the fundamental implications.

In any case, this was the catalyst above all others and it came a full quarter sooner than expected. Just beautiful.

[Ry🅰️n O'Connor @AboveAvgOdds]

@mc_khristina Hard to imagine how we don’t 2-3x on the news given the fundamental implications.

In any case, this was the catalyst above all others and it came a full quarter sooner than expected. Just beautiful.

[DVD @deepvaluedude]

$MRLN
I just bought 20,000 more shares in the AH. MAJOR de-risking event.

[Anp🅰️nman @spacanpanman]

$MRLN: 🔥 Real-time short interest at all-time high. Borrow rate high as well 😁

6/3: 4.6M 37%
6/2: 4.2M 37%
6/1: 3.9M 37%
5/29: 3.8M 36%
5/28: 3.6M 38%
5/27: 3.4M 36%
5/26: 3.4M 36%
5/25: 3.3M 37%
5/22: 3.3M 35%
5/21: 3.1M 37%

[Uzo @Uzocapital]

$MRLN - very important progress + de-risking event.

This is a listed venture bet with the associated risks...but if they can deliver on the vision (autonomous pilots), the upside potential is HUGE.

[Merlin @MerlinAero]

Merlin has completed the Critical Design Review for its C-130J autonomy program with @USSOCOM. CDR is the milestone where our government customer reviews the detailed design of the system and accepts it is mature enough to move toward the aircraft. We cleared it.

Learn more about what this milestone means in the press release. https://t.co/Gfkg4jDxqV

[DVD @deepvaluedude]

@alc2022 $CMPS … psychedelics are the next biotech thematic. This will be the first company, by a long mile, to get FDA approval, most like within the next 12 months.

[DVD @deepvaluedude]

@mondkapitan Whats the timeline and profit margins on any of the crap you just laid out. Exactly.

[DVD @deepvaluedude]

$LUNR
Company lost a major contract last week, issued an ATM today, and a large holder gets their half of their shares unlocked next month (~7% of shares outstanding)…

This is a Rakuten selling $ASTS all over again, except this company doesn’t have the momentum bid or business fundamentals to hold up. So many overhangs on price makes a great short.

[DVD @deepvaluedude]

$LUNR
This is has to be the shittiest company I’ve come across in a long time. More on this later.

[DVD @deepvaluedude]

@corey407woc Stock is headed back to the teens by end of summer

[DVD @deepvaluedude]

@ijustinvest4fun I don’t have time to rage bait

[DVD @deepvaluedude]

@QTRResearch 100%

[DVD @deepvaluedude]

@citrini Psychedelics is the next thematic.

[DVD @deepvaluedude]

@defedeee1 Yes

[DVD @deepvaluedude]

$CMPS is the most asymmetric set up in biotech

[filip @filipsamardzicc]

$CMPS $DFTX $ATAI

“The White House said psychedelic compounds “show potential in clinical studies to address serious mental illnesses for patients whose conditions persist after completing standard therapy.”

Investors quickly piled into the sector. Shares of psychedelic drug developers such as Compass Pathways and other rivals tied to the space rallied following the announcement, with Wall Street analysts arguing the order could legitimize an industry long viewed as fringe.”

[BDigs @B__Digs]

$CMPS

https://t.co/5kSHXBlbBU

[DVD @deepvaluedude]

@hypergrowth102 I’m very long $CMPS …

[DVD @deepvaluedude]

$LUNR
This is has to be the shittiest company I’ve come across in a long time. More on this later.